Wockhardt gains usfda approval for zaynich antibiotic

Kiswahili

Wockhardt has secured USFDA approval for its novel antibiotic Zaynich after 12 years of development. The drug targets multidrug-resistant bacteria and carries a projected peak sales potential of $1.5 billion. The approval has lifted investor sentiment, pushing the company's stock higher.

The approval marks a potential turning point for Wockhardt, which has posted net losses in recent years. Zaynich was developed to address infections resistant to existing treatments, filling a gap in the pharmaceutical market for new antibiotics.

Makala yanayohusiana

Lab illustration of madecassic acid from Centella skincare inhibiting drug-resistant E. coli bacteria.
Picha iliyoundwa na AI

Study finds madecassic acid, a Centella compound used in skincare, can inhibit drug-resistant E. coli in lab tests

Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli

Researchers at the University of Kent, working with University College London, report that madecassic acid—a compound derived from the medicinal herb Centella asiatica and widely used in skincare—can inhibit the growth of antibiotic-resistant E. coli by targeting a bacterial respiratory system not found in humans or other animals.

British surgeon says AI can transform antibiotic resistance fight

British surgeon Ara Darzi told the WIRED Health conference that artificial intelligence is set to revolutionize the diagnosis and treatment of drug-resistant infections. He cautioned that insufficient incentives might block these innovations from reaching patients. Antibiotic resistance already causes over a million deaths worldwide each year.

Gland Pharma shares hit 52-week high after results

Imeripotiwa na AI

Gland Pharma shares reached a new 52-week high after the company reported strong results for the March quarter and full year. The European unit Cenexi showed signs of recovery while new product launches and capacity additions supported the outlook.

Asia

US reshoring casts shadow over China’s contract drug makers, analyst says

Biashara

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Afya

Scientists engineer probiotic bacteria to target mouse tumors

Mutual funds boost pharma and nbfc holdings in april

Indian fund managers directed fresh investments into pharmaceutical and non-banking financial companies during April. The moves targeted defensive stocks amid concerns over oil prices and tensions in West Asia.

Egypt explores pharma and healthcare investment with US firm

Imeripotiwa na AI

Egypt’s Ministry of Health has held talks with a US pharmaceutical company to discuss investment in healthcare and drug manufacturing. The meeting aims to attract foreign capital and boost local production capacity.

Jumapili, 24. Mwezi wa tano 2026, 11:37:04

Sun Pharma reports strong quarterly growth but eyes margin pressure

Ijumaa, 15. Mwezi wa tano 2026, 02:19:34

ARS Pharmaceuticals reports strong start to 2026 in earnings call

Jumanne, 12. Mwezi wa tano 2026, 13:13:48

Verrica pharmaceuticals holds q1 2026 earnings call

Jumatatu, 4. Mwezi wa tano 2026, 23:12:57

Pharco Pharmaceuticals plans EGP 1.5bn investments for production and export expansion

Alhamisi, 30. Mwezi wa nne 2026, 05:54:02

Syntara reports positive FDA feedback on amsulostat trial

Jumapili, 26. Mwezi wa nne 2026, 12:25:49

Sun Pharma shares jump over 9% on $11.75 billion Organon acquisition

Jumatano, 1. Mwezi wa nne 2026, 16:58:42

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Jumapili, 29. Mwezi wa tatu 2026, 08:38:05

CK Life unit Sequencio eyes China fast track for cancer vaccines

Tovuti hii inatumia vidakuzi

Tunatumia vidakuzi kwa uchambuzi ili kuboresha tovuti yetu. Soma sera ya faragha yetu kwa maelezo zaidi.
Kataa